RxDoctor Payments Data

Judith Valencia, MD

General Practice · Miami, FLNPI 1649478389

Payments from drug & device makers

$839in general payments, 2019–2025

Across 43 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$247
  • Amgen$200
  • Novo Nordisk$66
  • Johnson & Johnson$48
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$47
  • Smith+Nephew$42
  • plus $188 from 7 others

What the payments were for

  • Food & beverage$839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$839 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$11,569
Medicare patients
45
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$82,125
OzempicSemaglutide78$78,480
JanuviaSitagliptin Phosphate40$57,402
FarxigaDapagliflozin Propanediol36$28,608
XareltoRivaroxaban30$26,073
ProliaDenosumab14$24,275
ZenpepLipase/Protease/Amylase19$19,377
JanumetSitagliptin Phos/Metformin Hcl22$18,424
MyrbetriqMirabegron17$13,535
Tadalafil37$12,478
SymbicortBudesonide/Formoterol Fumarate46$10,477
VascepaIcosapent Ethyl15$10,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,380
Breo ElliptaFluticasone/Vilanterol16$7,348
Spiriva RespimatTiotropium Bromide12$6,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$17$85,34286 claims
Novo NordiskOzempic$66$78,48078 claims
AstraZenecaFarxiga, Symbicort$247$39,08582 claims
Johnson & JohnsonXarelto$48$26,07330 claims
AmgenProlia$200$24,27514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →